You are here: Industry Insights > Breast Cancer

News List

USFDA denies application from SPARC for cancer drug expresspharma
February 24, 2021
The Office of New Drugs of the US FDA requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis NDA.
UK grants marketing authorisation to “landmark” breast cancer therapy europeanpharmaceuticalreview
February 23, 2021
Seagen’s Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
FibroGenesis Reports Positive Data in Pancreatic, Breast Cancer Using Fibroblast-Based Immunotherapy americanpharmaceuticalreview
February 20, 2021
FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
NICE rejects Lilly’s Verzenios for advanced breast cancer pharmatimes
February 19, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.
Researchers identify existing drug’s potential for triple negative breast cancer pharmatimes
January 29, 2021
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).
Research finds decrease in radiotherapy treatments due to COVID-19 pharmatimes
January 27, 2021
New research has revealed ‘dramatic changes’ in the delivery of radiotherapy treatments for cancer during the first wave of the COVID-19 pandemic in England.
Therapeutic Solutions Reports Successful Treatment of Breast Cancer using StemVacs Cellular Immunotherapy americanpharmaceuticalreview
January 22, 2021
Therapeutic Solutions reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs™ cellular immunotherapy.
Enhertu bags EU approval for HER2-positive breast cancer pharmatimes
January 21, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been granted a conditional approval in the EU.
Anixa, Cleveland Clinic Announce FDA Clearance to Initiate Breast Cancer Vaccine Trial americanpharmaceuticalreview
January 08, 2021
Anixa Biosciences announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that it has ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page